PCC incubator network
The arithmetic that rules out a standalone captive does not rule out a captive.
A standalone captive costs somewhere between $50,000 and $150,000 a year to operate — management, actuarial, audit, tax, and regulatory fees — and that figure barely moves with size. It also requires dedicated capital, commonly $250,000, which then sits on the parent’s balance sheet earning very little.
Those two facts are why more than half of the captive licences Vermont has ever issued have since closed. Below a certain premium volume the fixed cost eats the benefit, and no amount of enthusiasm changes the arithmetic.
A protected cell shares that fixed cost across participants while keeping each participant’s assets and liabilities statutorily separate. It is the structurally honest answer for a company whose loss history justifies risk retention but whose premium volume does not yet justify its own insurance company.
Cross-liability segregation
What “protected” actually protects, and what it does not.
A protected cell company is a single legal entity containing a core and any number of cells. Each cell holds its own assets and liabilities. The governing statute provides that the assets of one cell are not available to meet the liabilities of another, so a catastrophic loss in one participant’s cell cannot reach into yours.
In practice this means three things worth being precise about. Your cell’s assets answer only for your cell’s liabilities. A creditor of another cell has no claim on your cell’s assets. And an insolvency in one cell does not automatically put the others into wind-up.
Now the part most cell marketing material leaves out. Cell segregation rests on statute, and it has been tested in very few courts. A US court applying US law is not automatically bound to respect another jurisdiction’s segregation statute, particularly where a claimant sues the PCC rather than the cell. The core itself is generally not segregated from cell liabilities in the same way, so a core-level failure is a genuine shared exposure. And a cell is not a separate legal person in most domiciles, which affects how it contracts, how it is sued, and how it is taxed.
None of that makes a cell a bad structure. It makes cell segregation a legal protection with a real but bounded scope — which is exactly how it should be presented to a board, rather than as an absolute firewall.
Premium allocation
Credibility weighting, because a small company’s own experience is not the whole story.
The hard problem in a shared structure is deciding what each participant pays. Two wrong answers are easy to reach and both are unstable.
Charge everyone the manual rate
Ignores loss experience entirely. The good risks are overcharged, realise it, and leave — which is precisely how a shared pool unravels. Adverse selection is not a theoretical risk here; it is the default outcome.
Charge everyone their own experience
Intuitive and statistically wrong at small volumes. A company with four claims a year has an observed loss rate dominated by noise. Pricing off it means whipsawing premiums that reflect luck rather than risk.
Credibility weight the two
Blend the participant's own experience with the pool's, weighted by how much statistical credibility the participant's own data actually carries. More exposure and more claims earn more weight on your own record. This is standard actuarial practice, and it is the only allocation that is stable as participants join and leave.
Allocation is computed from each participant’s exposure base, claim count, and incurred losses, with the credibility weight shown explicitly rather than applied behind the scenes. A participant who cannot see why they are being charged what they are being charged will not stay in the pool, and they would be right not to.
When to say no
A cell is often the wrong answer too.
If your losses are genuinely unpredictable at your size, retaining them in any structure converts an insurance premium into balance-sheet volatility. That is a worse trade, not a cleverer one.
If the commercial market is pricing your risk below its expected cost — which happens in a soft market — a captive or cell captures no arbitrage. It just takes on risk you were previously paying someone else to carry cheaply.
If the motivation is primarily a tax deduction, stop. That is the fact pattern the IRS has litigated repeatedly and largely won. A captive must be insurance in substance, with real risk shifting and risk distribution, priced at arm’s length. Tax treatment is a consequence of a legitimate structure, never the reason for one.
If you cannot fund the capital without straining, the structure will fail in its first bad year and the capital call will arrive at the worst possible moment.
The analysis on this platform tests all four. It is willing to tell you that a cell does not make sense, and it costs the same when it does.
Enquire about membership
Start with the arithmetic, not the enthusiasm.
Run a study first. If the numbers say a cell is right for you, membership is $9,999/yr. If they say it is not, you will have that answer for the price of a study rather than the price of a formation.